PHARMACEUTICAL DRUG DISCOVERY

  • Get in vivo efficacy results in days
  • Apply principles of the 3Rs to avoid pitfalls and expenses of mouse testing
  • Obtain large genetic overlap with human disease genes in an invertebrate animal model

Percentage of Disease Genes with Homologs in C. elegans

65%

Our microfluidic system quickly screens compounds using C. elegans, a proven model system. Like mice, this species is genetically tractable and has endogenous versions of many known human disease genes.  Where endogenous genes lack, C. elegans can be humanized or genetically engineered to contain human genes.  C. elegans reach adulthood in a mere three days, allowing our customers to get results quickly.

Protect yourself against translational failures by diversifying across species during compound testing.  While mice are still the gold standard, exclusive testing on mice is expensive and amplifies the “pipeline problem”  identified by the FDA  in its Critical Path Initiative report.  Our products can provide support for many of the stages of drug discovery, including in vivo efficacy and toxicology testing.  Incorporating other model organisms into compound testing isn’t just smart science; it’s smart business.

Selected Citations


Modeling neurodegenerative diseases in Caenorhabditis elegans.

C. elegans: model host and tool for antimicrobial drug discovery.

Caenorhabditis elegans: a versatile platform for drug discovery.

“If we do not work together to find fundamentally faster, more predictable, and less costly ways to turn good biomedical ideas into safe and effective treatments, the hoped-for benefits of the biomedical century may not come to pass, or may not be affordable.”

FDA Critical Path Initiative  

Challenges and Opportunities Report